What Zepbound is
Zepbound® is tirzepatide, made by Eli Lilly: one molecule that activates the receptors for GIP and GLP-1, two hormones released from the gut after a meal [1]. It is FDA-approved, with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity, or with overweight and a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity [1].
The sleep apnea approval, in December 2024, made it the first medicine approved for that condition in some patients; the FDA linked the improvement in breathing to the weight it helps people lose [2]. Mounjaro® is the same ingredient from Lilly, approved for type 2 diabetes rather than weight.
How Zepbound works
GLP-1 regulates appetite and calorie intake. Zepbound® also activates the receptor for GIP, which studies outside people suggest may add to the effect on food intake, and receptors for both sit in the brain’s appetite centers. According to the label, it lowers calorie intake, the weight it lowers is more fat than lean mass, and it slows stomach emptying, most after the first dose [1]. NIDDK is clear that medicines like it work with healthier eating and more activity, not in place of them [3].
The pen
- KwikPen®: each pen holds 4 weekly doses, one month of treatment. It is for one person only and is never shared, even with a new needle [1].
- Where and when: under the skin of the stomach or thigh, or the back of the upper arm if someone else injects it, at any time of day, with or without food, rotating the site each week [1].
- Price: the VevaMD membership stays the same at every strength; Eli Lilly sets the self-pay price for each strength.
How you get Zepbound through VevaMD
Zepbound through VevaMD is two separate payments. The VevaMD membership, $149/mo or less when you prepay three months, pays for your board-certified physician, the prescription and your follow-up. The medication is paid to Eli Lilly at its self-pay price through LillyDirect®, which ships the pen to you. VevaMD does not charge you for the medication, and the full schedule is in the price section above.
- Complete the intake. A physician licensed in your state reviews your history, including any sleep apnea diagnosis.
- If Zepbound® is right for you, the prescription goes to LillyDirect®.
- Set up your LillyDirect® account and pay Eli Lilly there; keep refills on time, because Lilly’s self-pay price for the higher strengths depends on refilling within 45 days.
- Your physician manages each step-up and the check-ins after it, for the same membership price.
Who Zepbound is for
Approved for
What the trials found
Weight. SURMOUNT-1 assigned 2,539 adults with obesity or overweight, without diabetes, to one of three maintenance strengths of tirzepatide or to placebo for 72 weeks. Average weight change was -15.0%, -19.5% and -20.9% on the three strengths and -3.1% on placebo, and at the two higher strengths half or more lost at least 20% of their weight, against 3% on placebo. Every cardiometabolic measure the trial set out to track improved on tirzepatide [4]. Participants averaged 38 in BMI at the start, and most were women [1].
Head to head. In SURMOUNT-5, 751 adults with obesity took tirzepatide or semaglutide, each at the highest dose they tolerated, for 72 weeks. Weight fell by an average of 20.2% on tirzepatide and 13.7% on semaglutide, and waist size by 18.4 cm against 13.0 cm [5].
Sleep apnea. The approval rests on two 52-week studies of 469 adults with obesity and moderate to severe sleep apnea, one in people using CPAP and one in people unable or unwilling to use it [2]. In the trial of people not using CPAP, breathing interruptions during sleep fell by about 25 events an hour on Zepbound against about 5 on placebo after 52 weeks, and 42% reached remission or mild apnea without daytime sleepiness, against 16% on placebo [1].
What to expect over time
- The first monthEveryone starts on the lowest strength for 4 weeks, so the body can get used to the medicine [1].
- Months 2 to 5Step-ups at least 4 weeks apart until your physician and you settle on a maintenance strength [1]. Nausea and other stomach effects mostly show up during these step-ups [4].
- Months 6 to 18In SURMOUNT-4, people who stayed on tirzepatide after 36 weeks lost a further 5.5% over the next year, for a total of 25.3% from the start [6].
- If you stopThose switched to placebo in SURMOUNT-4 regained 14.0% of their weight within a year [6]. Zepbound is a long-term treatment, and your physician plans any change with you.
Side effects and the boxed warning
| Side effect | Zepbound® | Placebo |
|---|---|---|
| Nausea | 28% [1] | 8% |
| Diarrhea | 23% [1] | 8% |
| Vomiting | 13% [1] | 2% |
| Constipation | 11% [1] | 5% |
| Stomach pain | 10% [1] | 5% |
| Injection-site reactions | 8% [1] | 2% |
In SURMOUNT-1, side effects led 4.3% to 7.1% of people on tirzepatide to stop, against 2.6% on placebo [4]. The label’s serious risks include severe stomach side effects, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, low blood sugar with insulin or a sulfonylurea, diabetic eye complications, and aspiration during anesthesia [1].
Staying with it. Zepbound® treats a chronic disease. The Obesity Medicine Association notes that stopping a medicine like it carries a high risk of weight regain [7], and NIDDK points to at least 150 minutes a week of moderate activity to help keep weight off [3]. The Endocrine Society’s guideline treats these medicines as adjuncts to lifestyle change [8], which is how your physician builds the plan.
Zepbound compared with the other options
Your physician can recommend any of the four from one intake. Compounded tirzepatide is prepared by a pharmacy and is not FDA-approved or Zepbound®; Wegovy® is the FDA-approved semaglutide brand, as a pen or a pill.
| FDA status | How it is taken | How you pay at VevaMD | Main trade-offs | |
|---|---|---|---|---|
| Compounded semaglutide | Compounded, not FDA-approved | Weekly injection from a vial, with vitamin B12 | One monthly price, as low as $199/mo: physician, medication and shipping. No membership fee | The lowest monthly price, the same at every dose; you draw each dose with a syringe |
| Compounded tirzepatide | Compounded, not FDA-approved | Weekly injection from a vial, with vitamin B12 | One monthly price, as low as $299/mo: physician, medication and shipping. No membership fee | Acts on two gut-hormone receptors, GLP-1 and GIP; the same price at every dose; you draw each dose with a syringe |
| Wegovy® | FDA-approved brand | Weekly prefilled pen, or a daily tablet | A $149/mo VevaMD membership, plus the self-pay price paid to Novo Nordisk ($348–$498/mo in total for the pen) | Approved for weight and to lower heart risk in adults with heart disease; pen or pill; two separate charges |
| Zepbound® | FDA-approved brand | Weekly prefilled pen | A $149/mo VevaMD membership, plus the self-pay price paid to Eli Lilly ($448–$598/mo in total) | Approved for weight and for moderate to severe sleep apnea with obesity; prefilled pen; two separate charges |
Weight gain in perimenopause and menopause
Women in the menopause transition often find that the same habits no longer hold their weight. In SWAN, a long-running study of midlife women, fat gain sped up to twice its earlier rate as the transition began and lean mass started to decline [9]. Lower estrogen also shifts fat to the abdomen, and hot flashes and poor sleep get in the way of the routines that help [10].